Axovant Sciences Ltd (NYSE:AXON) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.

A number of other research firms have also recently weighed in on AXON. Chardan Capital restated a “sell” rating and set a $3.00 price objective on shares of Axovant Sciences in a research report on Saturday, September 23rd. JMP Securities restated an “outperform” rating and set a $19.00 price objective (down from $36.00) on shares of Axovant Sciences in a research report on Tuesday, September 26th. Robert W. Baird cut shares of Axovant Sciences from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $29.00 to $6.00 in a research report on Tuesday, September 26th. Piper Jaffray Companies cut shares of Axovant Sciences from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $32.00 to $9.00 in a research report on Tuesday, September 26th. Finally, Oppenheimer Holdings, Inc. cut shares of Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $14.13.

Axovant Sciences (AXON) opened at 6.17 on Tuesday. Axovant Sciences has a 1-year low of $6.08 and a 1-year high of $27.98. The stock’s market capitalization is $663.43 million. The company’s 50-day moving average is $15.59 and its 200 day moving average is $20.33.

Axovant Sciences (NYSE:AXON) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). Equities analysts predict that Axovant Sciences will post ($2.02) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Axovant Sciences Ltd (AXON) Cut to “Sell” at BidaskClub” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-cut-to-sell-at-bidaskclub/1635436.html.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC grew its holdings in shares of Axovant Sciences by 968.5% in the second quarter. FMR LLC now owns 7,235,632 shares of the biotechnology company’s stock valued at $167,794,000 after purchasing an additional 6,558,462 shares during the period. Capital Research Global Investors grew its holdings in shares of Axovant Sciences by 21.8% in the second quarter. Capital Research Global Investors now owns 3,453,800 shares of the biotechnology company’s stock valued at $80,094,000 after purchasing an additional 619,226 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Axovant Sciences in the second quarter valued at about $47,854,000. State Street Corp grew its holdings in shares of Axovant Sciences by 52.8% in the second quarter. State Street Corp now owns 546,920 shares of the biotechnology company’s stock valued at $12,682,000 after purchasing an additional 188,945 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Axovant Sciences by 4.1% in the first quarter. JPMorgan Chase & Co. now owns 489,024 shares of the biotechnology company’s stock valued at $7,306,000 after purchasing an additional 19,129 shares during the period.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.